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Objectives: The recently published EQ-5D-Y valuation protocol prescribes the general public values EQ-5D-Y health states for a
10-year-old child. This child perspective differs from the individual perspective applied for valuation of adult EQ-5D
instruments. This article discusses the rationale for and implications of applying a child perspective for EQ-5D-Y health
state valuation.
Methods: This article was informed by an exploration of the normative and empirical literature on health state valuation. We
identified and summarized key discussion points in a narrative review.
Results: Although valuing EQ-5D-Y health states from an individual perspective is feasible, it may be problematic for several
reasons. The use of a child perspective implies that—rather than valuing one’s own health—someone else’s health is valued.
This may require the projection of one’s own beliefs, expectations, and preferences on others, which could change the
decision processes underlying the elicited preferences. Furthermore, because preferences are obtained for a 10-year-old
child, it is unclear if this given age as well as other (missing) information on the described child beneficiary (should)
affect valuation of EQ-5D-Y health states.
Conclusions: The change from an individual to a child perspective in the valuation of EQ-5D-Y will likely lead to differences in
utilities. This has implications for the estimation of incremental health-related quality-of-life gains in economic evaluations of
health technologies for children and adolescents and therefore might affect reimbursement decisions. Further research is
necessary for gaining insight into the extent to which this impact is normatively and empirically justified.
Keywords: adolescents, children, EQ-5D-Y, health-related quality of life, health state valuation, QALY.
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Economic evaluations of new health technologies are increas-
ingly used in child and adolescent patient populations.1 In eco-
nomic evaluations, treatment-related health gains are often
expressed in quality-adjusted life-years (QALYs), as this facilitates
the comparison of health gains across health technologies and
patient populations.2 QALYs are calculated by multiplying gains in
life expectancy by a weight that represents the utility or value
associated with the health-related quality of life (HRQOL) expe-
rienced during that time. The HRQOL component of the QALY is
normalized such that the utility of perfect health equals 1 and of
being dead equals 0. HRQOL can be assessed with the use of
generic outcome measures, of which EQ-5D instruments are often
recommended by decision bodies dealing with health technology
assessment and appraisal.3-5
EQ-5D instruments are used to describe and measure a broad
range of health states (see text box 1). The utilities associated with
each of these health states can be based on preferences that are15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/belicited directly from persons who experience or experienced
living in these health states, such as patients.8-10 Nevertheless,
utilities can also be based on preferences that are elicited indi-
rectly from persons who (may) lack that experience. The latter
approach is referred to as indirect, because the EQ-5D is used to
assess patients’ HRQOL, while the utility associated with the
(possible change in their) health state is not based on their own
preferences, but rather on preferences of a sample of adult
members of the general public. EQ-5D valuation studies obtain
these preferences by using a standardized valuation protocol that
enhances data quality and comparability between valuation
studies in countries.11 This protocol employs a combination of
composite time trade-off (cTTO) and discrete choice experiment
(DCE) valuation tasks.12 These tasks are completed by adult
members of the general public who imagine themselves living in
the EQ-5D health states under valuation.11 In this article, this is
referred to as the individual perspective.
Interest in measurement and valuation of HRQOL in child and
adolescent patient populations is also increasing.1 This led to theHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
TEXT BOX 1. EQ-5D instruments: EQ-5D-3L, EQ-5D-5L and EQ-5D-Y
Currently, 3 EQ-5D instruments are available for describing and measuring health-related quality of life, ie, the EQ-5D-3L, EQ-5D-5L,
and EQ-5D-Y.6 Use of the EQ-5D-3L or EQ-5D-5L is recommended for persons aged 16 and older. The descriptive systems of these
instruments comprise the dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.7 Depending on
whether the EQ-5D-3L or EQ-5D-5L is used, each dimension has three or five problem levels (ranging from having “no problems” to
“extreme problems,” or “being unable to”). The best health state described by the EQ-5D instruments is coded as 11111 and
describes a health state with “no problems” in any of the dimensions. The worst health state is coded as 33333 by the EQ-5D-3L and
as 55555 by the EQ-5D-5L and describes “extreme problems” or “being unable to” in all dimensions. The EQ-5D-3L descriptive
system describes a total of 243 (35) unique health states and that of the EQ-5D-5L describes a total of 3,125 (55) health states.
Compared to the adult instruments, the wording of the dimensions and levels of EQ-5D-Y are slightly different such that they are
suitable for use in child and adolescent populations. The following 5 dimensions are used: mobility (walking about), looking after
myself, doing usual activities, having pain or discomfort, and feeling worried, sad or unhappy. Furthermore, the dimension “usual
activities” is described by means of child-relevant examples, such as “going to school” and “playing,” rather than “going to work” and
“doing housework.” The levels in in the 3L version of EQ-5D-Y are “no problems,” “some problems” and “a lot of problems,” with a
slight change for feeling worried, sad or unhappy (this uses the labels: “not”, “a bit” and “very”).
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reported HRQOL for children and adolescents aged 8 to 15. The
instrument is adapted from the EQ-5D-3L,13,14 and hence has a
similar descriptive system, except for some differences in wording
of the dimensions and problem levels (see text box 1). Throughout
this article we refer to this instrument as EQ-5D-Y, because the
points discussed in this article likely apply to the instrument
currently used as well as the 5-level version of the EQ-5D-Y that is
still under development.15 Furthermore, much of what is dis-
cussed may also apply to other child and adolescent HRQOL
instruments.16
Amid ongoing discussion about the sample, type of valuation
tasks, and perspective used for valuation of child and adolescent
health states,17,18 the valuation protocol for the EQ-5D-Y was
published,19 which resembles the protocol used for valuation of
adult EQ-5D health states.11 It includes the same sample of the
adult general public and combination of valuation tasks (although
the emphasis has shifted from cTTO to DCE tasks). Nevertheless,
the protocol prescribes that the valuation tasks are completed
while considering the health of a 10-year-old child.19 This involves
a 3-fold change in the perspective used: (1) respondents do not
value health states for themselves but for someone else, (2) they
do not value health states for an adult but for a child, and (3) they
do not value health states for any child but specifically for a 10-
year-old child.19 In this article, this will be referred to as the
child perspective.
Whereas the rationale for and implications of the choice for
sample and valuation tasks used for developing EQ-5D-Y value
sets have been broadly discussed,17,18,20 the choice for using a child
perspective has received less attention. A critical evaluation of the
consequences of this choice appears relevant, because earlier
research has shown that the use of a child perspective, rather than
an individual perspective, yielded different utilities for EQ-5D-Y
health states.21,20,22-24 For cTTO the evidence points at higher
utilities when valuation for EQ-5D-Y is performed with a child
perspective,21,23,24 whereas for visual analog scales the direction
of this effect is ambiguous.22,24,25 Hence, the objective of the
current article is to address this gap and discuss the rationale for
and implications of the choice for using a child perspective for
valuation of EQ-5D-Y health states. Rather than suggest further
changes to the perspective are necessary, our main motivation is
to facilitate interpretation of the results of the first EQ-5D-Y
valuation studies26,27 and to suggest directions for future research.
The article is structured as follows. We first discuss the ratio-
nale for using an individual perspective in valuation of adultEQ-5D health states and why this perspective may be inappro-
priate for valuation of the EQ-5D-Y. Next, we discuss the norma-
tive and practical implications of the change from individual to
child perspective for valuation of the health states. Subsequently,
we discuss the possible implications of using a child perspective
for the estimation of incremental HRQOL gains in economic
evaluations of health technologies for children and adolescents.
We conclude with a discussion of several directions for future
research.Rationale for (Not) Using an Individual
Perspective
In earlier work exploring the normative framework for valua-
tion of the EQ-5D and related instruments, the rationale provided
for the choice of perspective and sample have been inextricably
linked. It seems worthwhile to summarize this rationale, and
explore the rationale provided for a child perspective in valuation
of the EQ-5D-Y.19
EQ-5D valuation studies so far have exclusively elicited pref-
erences using an individual perspective in a sample of adult
members of the general public.28-31 Earlier work exploring the
rationale for valuation with such an indirect approach suggested
the following arguments: (1) adaptation— a general public sample
is preferred because patients may adapt to their conditions and
employ coping strategies (eg, denial or shifting expectations), and
consequently may overestimate the utility associated with their
health state; (2) payer perspective—in publicly financed healthcare
systems, the utilities used for economic evaluation should reflect
preferences of those who collectively bear the costs of healthcare
(or could influence healthcare spending through voting); and (3)
veil of ignorance—patients may have a vested interest in the
reimbursement of new health technologies and this could affect
the valuation of their health state and, as such, utilities should
reflect preferences of individuals who are not certain that they
will ever become patients (see reviews8,32).
In the article describing the development of the EQ-5D-Y
valuation protocol, Ramos-Goni et al19 appear to take this payer
perspective. That is, they state that the protocol will continue
eliciting preferences from the taxpaying public, because this can
be considered fair considering that they bear the costs of health-
care. Furthermore, the authors argue that including children, and
to a lesser extent adolescents, in health state valuation is disputed,
as the valuation tasks may be considered to be too complex or
-- 3ethically undesirable. For example, it may be ethically undesirable
or burdensome to ask children and adolescents to imagine their
own foreseeable or immediate death in the cTTO tasks.18 Never-
theless, no further rationale is provided for using a child
perspective for EQ-5D-Y valuation. In fact, the authors argue it
may be considered arbitrary and may hamper the comparison
between EQ-5D and EQ-5D-Y valuation studies.19
Hence, one could question why a change in perspective for
valuation of EQ-5D-Y health states would be necessary, because
valuation of EQ-5D-Y health states from an individual perspective
would, in theory, be possible.
Why May an Individual Perspective for Valuation of EQ-
5D-Y Health States Be Inappropriate?
Nevertheless, valuation of EQ-5D-Y health states by a general
public sample with an individual may be considered inappropriate
for (at least) 2 reasons.
First, it may not be possible to fully extend the rationales
provided for applying an individual perspective for valuation of
adult EQ-5D health states to the EQ-5D-Y. As mentioned above, for
valuation of adult EQ-5D instruments this approach is justified by
arguing that it includes the preferences of those bearing the costs
of treatments, before knowing if, when, and for which health state
they will need treatment (ie, no vested interests). In other words,
the use of an individual perspective in EQ-5D valuation aligns with
the preferences of those bearing costs of treatments evaluated by
the instrument with those whose benefits can (in principle) be
captured by the instrument. By contrast, when adults of the
general public value EQ-5D-Y health states for themselves, these
states are drawn from an instrument that is not intended to
capture their health benefits in the first place. At the same time,
the preferences of children and adolescents, for whom the EQ-5D-
Y is intended and, thus, may—at some point—experience the
HRQOL described by it, are excluded. As a result, there is no longer
direct alignment between preferences of those bearing the costs of
those whose possible benefits EQ-5D-Y can capture. Extending the
individual perspective to EQ-5D-Y valuation may only realize this
alignment when members of the general public benefit indirectly
from health improvements in children and adolescents measured
by the EQ-5D-Y (eg, through their children), which may not be the
case for all respondents. The normative implications of this lack of
alignment between payers and (possible) beneficiaries in EQ-5D-Y
valuation are unclear.
Second, by eliciting preferences from adult members of the
general public with an individual perspective, the estimated util-
ities may not reflect aspects of HRQOL that are considered
important by children and adolescents aged 8 to 15, for whom the
instrument is intended. For example, it is conceivable that some
health problems, for example, associated with self-care and doing
usual activities, may be considered more acceptable for young
children than for adults,33 as the former are often assisted by adult
caregivers. Nevertheless, similar health problems may be
considered less acceptable for adolescents, for whom the use of
the EQ-5D-Y is also recommended. Before the introduction of the
EQ-5D-Y, EQ-5D value sets have not been developed with the
explicit aim of reflecting preferences for a single age. Rather, age-
specific preferences were aggregated and therefore (implicitly)
included in the value set. Some authors see this as problematic,34
because this aggregation is insufficiently sensitive to preference
heterogeneity, and age is a demonstrable source of heterogeneity
in valuation of the EQ-5D.35 Extending the individual perspective
to the valuation of the EQ-5D-Y would imply that only adults’
age-specific preferences are considered, while excludingage-specific preferences for and of children and adolescents
themselves.Implications of Using a Child Perspective for
Valuation of EQ-5D-Y Health States
Even though the choice for a child perspective can be consid-
ered arbitrary,19 it may still create the opportunity to explicitly
take into account preferences associated with the health states of
a younger age group. Hence, rather than discussing other possible
perspectives and their (lack of) normative justification, a discus-
sion of the possible implications of a child perspective may help in
interpreting results from extant and future valuation studies. To
date, existing work suggest that health states are valued differ-
ently between individual and child perspectives.21,22,23,36 These
differences could result from (at least) 2 changes implied by the
use of a child perspective. First, decisions are made for another
person and this may introduce (additional) uncertainty in a
valuation study. Second, the health states are described for a 10-
year old child and (the lack) of additional information may in-
fluence the decision-making process and resulting preferences of
respondents.Uncertainty About Another Person’s Beliefs, Preferences,
and Goals
The economic literature suggests that decisionsmade for others
differ in many respects from decisions made for oneself,37-40
because they are affected by uncertainty about the other person’s
beliefs, preferences, and goals.41 Hence, EQ-5D-Y valuation may be
affected by the degree towhich respondents arewilling and able to
impose their own beliefs on someone else. For example, consider
the choice between living 10 years in severe health state and im-
mediate death.Making such a choice froman individual perspective
is likely affected by one’s views on life after death and euthanasia as
well as the amount of time certain health states are perceived as
being bearable (ie, maximum endurable time42). The use of a child
perspective in valuation of the EQ-5D-Y thus requires respondents
to determine if these beliefs should apply to health states experi-
enced by another person.
Furthermore, the theoretical foundation that allows deriving
utilities from preferences (eg, the linear QALY model43) is based
exclusively on models of preferences for own health. Whether the
strict assumptions about preferences present in the theoretical
foundation of health state valuation hold (or are violated to the
same degree) when using a child perspective is, thus, unknown.
For example, linear utility of life duration is assumed (ie, no dis-
counting). When preferences are elicited with an individual
perspective, cTTO utilities have been argued to depend on time
preferences and loss aversion, which can be defined as the
importance assigned to recent relative to later years and over-
weighting of life-year losses.44,45 In this context, respondents
trade off their own health and, thus, their own preferences for
(losing) life expectancy are relevant. When a child perspective is
used, these trade-offs are completed with someone else’s life, and
preferences associated with loss aversion and discounting may be
different when they affect someone else.37,38
Moreover, evidence suggests that valuation of EQ-5D health
states may be influenced by respondents’ extrinsic goals46 and
expectations.47-49 Hence, the use of a child perspective may
introduce a tendency to consider such extrinsic goals for another
person during the valuation tasks (eg, graduation, reaching
adulthood, obtaining a driver’s license). Additionally, cTTO
4 VALUE IN HEALTH - 2021typically involves a significant reduction in life expectancy for the
beneficiary, which was shown to influence valuation in an indi-
vidual perspective.47-49 Individuals may differ in the degree to
which they are able to approximate another person’s goals and
expectations or be prone to project such considerations of their
own onto deciding for others. It is unclear if such heterogeneity
should be included in valuation of the severity of the health states
described.
Lack of Information on the 10-Year-Old Child
By asking respondents to consider a 10-year old child, the
beneficiary is described as having a specific age but no further
information is provided for who the child is and which relation-
ship the respondent has with the child. Hence, the use of a child
perspective implies that age is explicitly considered when
completing the cTTO and DCE valuation tasks, while other char-
acteristics are left ambiguous. Examples of how this may affect
valuation of EQ-5D-Y are discussed below.
The use of a child beneficiary may imply that if some di-
mensions of HRQOL are of different importance to children and
adolescents, these will be reflected in valuation. Nevertheless, this
only holds to the extent that adults are sufficiently aware of this
importance and deliberately consider it. It is, furthermore, unclear
if value sets derived based on the specific preferences for a child of
10 years old are applicable for the full age range relevant to the
EQ-5D-Y. This may be particularly true in cTTO tasks. Interestingly,
a substantial part of the life duration considered in cTTO does not
strictly involve time the beneficiary spends as a child. One could
question whether it is appropriate to derive EQ-5D-Y utilities from
trading off live years of a (young) adult, especially when lead time
is introduced in cTTO tasks.
The child perspective prescribed provides no details about the
imagined 10-year-old child other than age. This lack of context
may result in a more comprehensive value set in which various
preferences are implicitly taken into account. Nevertheless, it also
introduces heterogeneity in the child imagined. For example,
adults could imagine the beneficiary in health state valuation to be
a specific child (ie, their own child or another child known to
them) or a hypothetical child. Further, when respondents value
the health states for some imagined child and the characteristics
of these imagined children are diverse, this could introduce dif-
ferences in the relationship between the respondent and the
beneficiary. Such differences could be relevant for the valuation,
because these relationships could lead to different justifications
for having to decide for a child (without involving the child
himself/herself). That is, parents or guardian may have experience
with and be legally allowed to decide on behalf of children, which
may play a role if they imagine the beneficiary to be their own
child. Such a legitimate basis may be lacking for respondents with
different imagined child beneficiaries. It is currently unclear how
such heterogeneity affects EQ-5D-Y valuation, and whether
aggregating preferences for different imagined children is
desirable.Implications of Using a Child Perspective for
Estimation of Incremental HRQOL Gains
One may argue that some of the implications mentioned
above may be yet another source of heterogeneity in health
state valuation, requiring the recruitment of a sample that is
sufficiently representative of the general public. At this point,
however, it is unclear whether these implications affect EQ-5D-
Y valuation at all, and if they do, if valuation of the EQ-5D-Y
should reflect this heterogeneity. Currently, the limitedempirical evidence suggests that using a child perspective,
rather than an individual perspective, may yield higher utilities
for valuation of similar EQ-5D health states.21 Hence, using
utilities elicited from a child perspective rather than from an
individual perspective may have implications for the estimation
of incremental HRQOL gains in economic evaluations of health
technologies for children and adolescents. In particular, 2
possible implications arise.
First, if the most severe health states yield higher utilities
when elicited from a child perspective, this would result in a
narrower utility range between the best and worst health states
described by the instrument and, thus, in a smaller overall pos-
sibility for incremental HRQOL gain. Second, the utility associated
with incremental health gains may depend on whether a child or
individual perspective is used. That is, transitions between health
states across the severity scale may yield different incremental
utility depending on the perspective used to elicit them. To
illustrate how both implications could affect incremental costs per
QALY gained (and possibly reimbursement decisions), data from
Kreimeier et al21 are used in several straightforward examples (see
text box 2).
Given that the evidence is currently limited and formal value
sets for EQ-5D-Y have only just become available in some
countries,26,27 it is currently unclear whether and to what extent
these implications will actually occur. It is important to consider,
however, that if they occur, this may yield different estimations
of incremental HRQOL gain in patients for whom adult EQ-5D
instruments are used (elicited from an individual perspective)
and those for whom the EQ-5D-Y is used (elicited from a child
perspective). As such, this could yield different incremental costs
per QALY or reimbursement decisions for adults and children
(and adolescents). Hence, it is recommended to take these
possible implications into account and consider the extent to
which they align with societal preferences before implementing
EQ-5D-Y value sets in decision-making frameworks. Importantly,
although distinguishing between treatments for adults and
children and adolescents may be aligned with societal prefer-
ences,50-52 the use of EQ-5D-Y value sets should not be confused
with or replace explicit age-based priority setting in reim-
bursement decisions, for example, through applying equity
weights to QALY gains.50 EQ-5D-Y value sets capture the value
associated with incremental HRQOL in children and adolescents
from the perspective of the general public. Determining whether
these incremental gains should be prioritized relative to other
population groups requires direct comparisons among children,
adolescents, and other patient populations.Directions for Further Research
Further work on the role of perspective in valuation of the EQ-
5D-Y should explore and compare the rationale for and implica-
tions of alternative perspectives and alternative (imagined) child
beneficiary. The following examples could provide ideas for an
agenda for future research:
 It appears relevant to consider children and adolescents’ valu-
ation of EQ-5D-Y health states from an individual perspective,
and compare to general public valuation of the EQ-5D-Y using a
child perspective.20
 The effects of deciding for another person could be investigated
by comparing utilities for adults deciding for themselves and
another adult, or alternatively it may be explored if it is possible
and appropriate to ask 10-year-old children to value health
states with both an individual and child perspective.
Table 1. Mean cTTO utilities for four health states derived from Kreimeier et al.21
EQ-5D-Y health state FH: 11111 HS1: 11112 HS2: 22222 HS3: 32313 HS4: 33323 HS5: 33333 Range
Individual perspective 1.00 0.95 0.7 0.28 –0.02 –0.17 1.17
Child perspective 1.00 0.96 0.83 0.54 0.16 –0.14 1.14
cTTO indicates composite time trade-off.
Table 2. ICERs for treatments involving health states selected from Kreimeier et al.21
Cost per QALY HS5 – FH HS4 – FH HS1 – FH HS2 – HS1 HS3 – HS2 HS4 – HS3 HS5 – HS4
Individual perspective V39 743 V45 588 V930 000 V186 000 V110 714 V155 000 V310 000
Child perspective V40 789 V55 357 V1 162 500 V357 692 V160 345 V122 368 V155 000
Difference –V1046 –V9769 –V232 500 –V171.692 –V49.630 V32 632 V155 000
Note. All ICERs are calculated by: (5 3 46.500)/(5 3 (utility HSb – utility HSa)), where HSa and HSb are the states included (e.g. HS1-HS2).
FH indicates full health; ICER indicates incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TEXT BOX 2. Examples of implications of a child perspective on cost per QALY gained
Table 1 presents the mean cTTO utilities for five EQ-5D-Y health states, obtained by Kreimeier et al.21 using individual and child
perspectives (denoted HS1 to 5). These health states were selected to represent the 11112 to 33333 health-state range and
supplemented with the utility associated with full health (FH) for reasons of clarity. These data are used to illustrate in 2 examples
how the use of a child perspective, as compared to the use of an individual perspective, may impact the incremental cost per QALY
ratios of health technologies.
Example 1: A child perspective may result in a narrower utility range
Imagine a patient population with a remaining life expectancy of 5 years living in HS5. Now, a treatment becomes available that will
restore all patients to full health for those 5 years (ie, health state 11111) at a cost of V46 500 per patient. The health gains such a
treatment would yield depend on the perspective used: each patient gains 1.17 or 1.14 QALYs when an individual or child
perspective is used respectively. This small difference could yield different incremental cost-effectiveness ratios (ICERs), because
without discounting the individual perspective ICER is V39.743 per QALY while the child perspective ICER is V40.789 per QALY (see
Table 2). If we consider, on the other hand, a treatment returning patients from 33323 to FH, ICERs are affected to a much larger
degree. Now, the individual perspective ICER is V45.588 per QALY while for child perspective ICER is V55.357 per QALY. The use of a
child perspective, as such, could decrease cost-effectiveness and influence reimbursement decisions when these ICERs are
compared to relevant thresholds.
Example 2: Incremental differences between health states elicited from an individual or child perspective may or may not be affected
depending on severity of the health states
Treatments improving health from HS4 or HS5 to FH are perhaps unrealistic, with improvements between health states closer in
severity being more likely. The influence the use of a child perspective may have could differ depending on the severity of the health
states. For example, Table 1 shows that for HS2-HS1 increments, incremental health gains are smaller from a child perspective
compared to an individual perspective, while for HS4-HS3 increments the opposite holds. Assuming the same costs and 5-year
duration, Table 2 shows that the impact the use of a child perspective has on ICERs involving health states of different severity is
unclear.
-- 5 A combination of samples and perspectives, eg, adult and child
and adolescent preferences can be considered.18
 It might be relevant to explore the extent to which use of a child
perspective and the implications thereof concurs with view-
points of the taxpaying public and of decision makers in the
context of reimbursement decisions.Conclusions
The use of a child perspective is the main change prescribed in
the standardized valuation protocol developed for the EQ-5D-Y19
compared with the valuation protocol for adult EQ-5D in-
struments. Applying an individual perspective for valuation of the
EQ-5D-Y would be possible, but may not be suitable. As such, thechange to a child perspective seems warranted. Nevertheless, the
decision to value EQ-5D-Y health states from a child perspective
may have several implications for value sets and estimation of
incremental HRQOL gains for children and adolescents. Both
empirical and normative research is needed for interpreting the
results and implications of future EQ-5D-Y valuation studies.
Importantly, this article suggest that no single way forward exists
that is without problems. Whether the general public should or
should not be asked to think of the childrenwhile valuing EQ-5D-Y
health states ultimately remains a value judgment.Article and Author Information
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